Group 1 - The meeting emphasized the importance of implementing Xi Jinping's recent speeches and directives, focusing on the significant achievements during the "14th Five-Year Plan" period and the need to maintain confidence and determination for national rejuvenation [1][2] - The provincial government aims to enhance economic and social development by focusing on serving the public, enterprises, and grassroots, while promoting the "Three-Year" initiative and tackling eight key challenges [1] - There is a strong commitment to strict party governance, adherence to the central regulations, and fostering a positive work environment to ensure a good start for the "15th Five-Year Plan" [1] Group 2 - The meeting highlighted the need to fully implement Xi Jinping's important discussions on Taiwan and the overall strategy for resolving Taiwan issues, emphasizing the province's role in promoting cross-strait exchanges and cooperation [2] - The importance of grassroots engagement and effective research was stressed to ensure a thorough understanding of real situations, enabling better management of economic operations and stability [2] - The meeting called for a comprehensive approach to political supervision and the optimization of inspection methods to enhance the effectiveness of the provincial inspection system [2]

在巴塞罗那MWC大会召开前夕，英伟达宣布与包括诺基亚、思科、德国电信、T-Mobile、BT集团及 Booz Allen Hamilton在内的全球电信与基础设施巨头联合，承诺在开放、安全的AI原生平台上构建6G网 络。 英伟达创始人兼首席执行官黄仁勋周日表示，"AI正在重新定义计算，并推动人类历史上规模最大的基 础设施建设——电信业将是下一个。" 此次合作的核心是AI-RAN（人工智能无线接入网络）技术路线。T-Mobile首席执行官Srini Gopalan表 示，"随着6G成为AI时代的骨干网络，电信将成为数字经济的神经系统，支撑自主系统和智能产业的大 规模运转。"6G预计于2030年前后正式商用，最早将于2028年启动试验。 AI-RAN商业化提速，多家运营商入局 英伟达此次不仅停留于战略宣示，还宣布与T-Mobile、软银及Indosat Ooredoo Hutchison达成新的AI- RAN商业化合作，将相关技术从实验室推向实际部署。 围绕英伟达方案构建的生态系统正在扩展，涵盖Quanta Cloud Technology的现成系统、WNC Corp.的AI 优化室内外射频单元、Eridan C ...

来源：观点地产网 观点网讯：3月2日，复星国际有限公司发布公告称，基于对公司长期发展前景的判断，计划在公开市场 进行股份回购。 根据公告内容，复星国际认为当前公司股价未能充分反映长期价值，将于2025年度业绩公告发布后至 2026年股东周年大会日期间，回购不超过10亿港元的股份。 免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 此次回购计划依据2025年6月5日股东周年大会授出的购回授权，具体执行将由董事会根据市场情况酌情 决定。 数据显示，自2022年1月1日起至本公告日期，复星国际已持续在公开市场回购股份2.59亿股，累计金额 约11.9亿港元，占已发行股份总数的3.17%。 复星国际提示，股份回购将由董事会酌情决定，公司不保证回购的时间、数量或价格，投资者买卖股份 时务请审慎行事。 ...

公司认为，当前公司股价水准未能充分反映公司长期价值，基于对公司长期发展前景的判断以及对股东 利益的审慎考量，公司将于符合法律法规及监管要求的前提下，于授权范围内审慎及有序推进股份回购 安排。 根据公司股东于2025年6月5日举行的股东周年大会上授出的购回授权，公司计划于2025年度业绩公告发 布后至该购回授权届满即2026年股东周年大会日，于公开市场购回股份，回购总金额不超过10亿港元。 上述回购将按照相关法律法规进行，并以公司内部资源拨付。具体回购时间、价格区间及执行节奏，将 由董事会根据市场状况及公司资本结构管理需要审慎决定。 格隆汇3月2日丨复星国际(00656.HK)发布公告，自2022年1月1日起至本公告日期，公司已持续于公开市 场进行股份回购。截至本公告日期：(一)累计回购股份总数约为2.59亿股股份；(二)累计回购总金额约 为11.9亿港元；(三)累计回购股份约占本公告日期已发行股份总数的3.17%；上述股份回购均根据当时有 效的股东授出一般授权进行，并以公司内部资源拨付。 ...

Core Viewpoint - China Biologic Products (01177.HK) has received approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug, Rovaxitinib Tablets (brand name: Anxu®), for first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) [1] Group 1 - Rovaxitinib is a globally innovative small molecule inhibitor targeting both JAK and ROCK pathways, providing dual effects of anti-inflammation and anti-fibrosis [1] - The drug works by inhibiting the JAK1/2-STAT3/5 signaling pathway, reducing high levels of inflammatory cytokines produced by myeloid cells, thus improving splenomegaly and systemic symptoms [1] - Additionally, it suppresses ROCK1/2 to lower the polarization level of T helper cells and the burden of inflammatory cytokines in patients with myelofibrosis, further enhancing anti-inflammatory effects and supporting long-term disease control [1]

在一项多中心、随机、双盲、双模拟、阳性药物平行对照的II期临床研究(TQ05105-II-01)中，罗伐昔替 尼对比羟基尿用于治疗中危-2、高危骨髓纤维化患者展示出优异的疗效和良好的安全性。该研究共入组 107例患者，按2:1随机分组接受罗伐昔替尼15mg或羟基尿0.5g，每日两次口服治疗。 疗效方面，罗伐昔替尼组经独立影像评估委员会(IRC)评估的第24周脾脏体积较基线缩小≥35%(SVR35) 受试者所占的比例为58.33%，任意时间点达到SVR35受试者比例达63.89%，SVR35平均持续时间长达 8.31个月，最佳总症状评分改善≥50%(TSS50)率高达77.78%。安全性方面，罗伐昔替尼总体耐受性良 好，相关研究中≥3级不良反应发生率约40%，贫血发生率约40%，治疗终止率仅6.7%，均远低于芦可替 尼。 中国生物制药(01177)公布，该集团自主研发的国家1类创新药罗伐昔替尼片(商品名：安煦)已获得中国 国家药品监督管理局(NMPA)的上市批准，用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞增 多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)成年患者 ...

疗效方面，罗伐昔替尼组经独立影像评估委员会(IRC)评估的第24周脾脏体积较基线缩小 ≥35%(SVR35) 受试者所占的比例为58.33%，任意时间点达到SVR35受试者比例达63.89%，SVR35平均持续时间长达 8.31个月，最佳总症状评分改善≥50%(TSS50)率高达77.78%。安全性方面，罗伐昔替尼总体耐受性良 好，相关研究中≥3级不良反应发生率约40%，贫血发生率约40%，治疗终止率仅 6.7%，均远低于芦可 替尼。 除MF外，罗伐昔替尼在慢性移植物抗宿主病(cGVHD)治疗领域亦展现出突破性潜力。目前，该产品针 对cGVHD的研发进展顺利：在中国已进入III期临床试验阶段，并于2025年8月被中国国家药品监督管理 局药品审评中心(CDE)纳入突破性治疗药物程序;在美国已获准开展II期临床研究。 智通财经APP讯，中国生物制药(01177)公布，该集团自主研发的国家1类创新药罗伐昔替尼片(商品名： 安煦® )已获得中国国家药品监督管理局(NMPA)的上市批准，用于中危-2或高危的原发性骨髓纤维化 (PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF) 或原发性血小板增多症后骨髓纤维化(PE ...

Core Viewpoint - Fosun International (00656) has been actively repurchasing shares in the open market since January 1, 2022, believing that the current stock price does not reflect the company's long-term value [1] Group 1: Share Repurchase Details - The total number of shares repurchased to date is approximately 259 million shares, amounting to about 1.19 billion Hong Kong dollars, which represents approximately 3.17% of the total issued shares as of the announcement date [1] - The share repurchase is conducted under the general authorization granted by shareholders and funded by the company's internal resources [1] Group 2: Future Plans - The company plans to continue share repurchases within the authorized limits, with a total amount not exceeding 1 billion Hong Kong dollars, from the release of the 2025 annual results until the expiration of the repurchase authorization at the 2026 annual general meeting [1] - The specific timing, price range, and execution pace of the repurchase will be determined by the board based on market conditions and the company's capital structure management needs [1] - The company believes that executing the repurchase at the current valuation level aligns with the overall interests of the company and its shareholders [1]

Core Viewpoint - The company believes that its current stock price does not adequately reflect its long-term value and plans to continue share buybacks to enhance shareholder interests [1] Group 1: Share Buyback Details - The company has repurchased approximately 259 million shares since January 1, 2022, totaling around HKD 1.19 billion, which represents about 3.17% of the total issued shares as of the announcement date [1] - The share buybacks are conducted under the general authority granted by shareholders and funded through internal resources [1] - The company plans to repurchase shares in the open market with a total amount not exceeding HKD 1 billion from the release of its 2025 annual results until the expiration of the buyback authorization at the 2026 annual general meeting [1] Group 2: Future Buyback Strategy - The specific timing, price range, and execution pace of future buybacks will be determined by the board based on market conditions and the company's capital structure management needs [1] - The company emphasizes that executing buybacks at the current valuation level aligns with the overall interests of the company and its shareholders [1]

Stock Performance - On February 27, 2026, the stock price of Autohome (ATHM.N / 02518.HK) declined significantly, with the US stock market facing pressure, as the Nasdaq index fell by 0.92% and the S&P 500 index dropped by 0.43% [2] - Autohome's US stock (ATHM.N) decreased by 3.91%, while its Hong Kong stock (02518.HK) fell by 5.93%, both underperforming compared to the major market indices [2] Company Valuation - The closing price of Autohome's Hong Kong stock was 38.36 HKD, which is below key moving averages such as the 20-day moving average at 41.98 HKD, indicating a weak technical position [3] - The MACD indicator showed a negative divergence of -0.927, placing the stock in a weak zone, while the Bollinger Bands indicated that the stock price was close to the lower band at 39.16 HKD, reflecting strong short-term selling pressure [3] Market Liquidity - The trading volume for Autohome's Hong Kong stock was approximately 1.67 million HKD, with a turnover rate of only 0.01%, suggesting low liquidity that could amplify price volatility [4] - There has been a recent outflow of southbound funds from the Hong Kong market, with a net sell of 7.366 billion HKD on February 26, creating pressure on small and mid-cap stocks [4] Earnings Outlook - Autohome is scheduled to release its financial report on March 5, with market expectations indicating a year-over-year revenue decline of 12.69% for the fourth quarter of 2025 [5] - Some investors may be opting for risk aversion ahead of the earnings report, contributing to increased selling activity [5]